Search Results
You are looking at 1 - 2 of 2 items for
- Author or Editor: Christine E. Thomson x
- Refine by Access: All Content x
Abstract
OBJECTIVE
To determine whether cell-free DNA (cfDNA) was detectable in CSF samples from dogs, whether CSF sample volume impacted CSF cfDNA concentration measurement, and whether CSF cfDNA concentration was associated with CNS disease category or CSF RBC count (RBCC), nucleated cell count (NCC), or protein concentration, which could aid in the diagnosis of neurologic diseases in dogs.
SAMPLE
80 CSF samples collected from dogs with (n = 60) and without (20) clinical neurologic disease between February 2017 and May 2018.
PROCEDURES
Results for CSF RBCC, NCC, protein concentration, and cfDNA concentration were compared across CSF groups established on the basis of whether they were obtained from dogs with (case groups) or without (control group) clinical signs of neurologic disease In addition, 5 paired CSF samples representing large (3.0-mL) and small (0.5-mL) volumes, were used to evaluate whether sample volume impacted measurement of CSF cfDNA concentration.
RESULTS
cfDNA was detected in 76 of the 80 (95%) CSF samples used to evaluate parameters across disease categories and in all 5 of the paired samples used to evaluate whether sample volume impacted cfDNA quantification. There were no substantial differences in cfDNA concentrations identified between groups (on the basis of disease category or sample volume), and the CSF cfDNA concentration did not meaningfully correlate with CSF RBCC, NCC, or protein concentration.
CONCLUSIONS AND CLINICAL RELEVANCE
Although results indicated that the CSF cfDNA concentration could not be used to differentiate between categories of neurologic disease in dogs of the the present study, further investigation is warranted regarding the use of CSF analysis, including sequencing specific cfDNA mutations, for diagnosing and monitoring neurologic disease in dogs.
Summary
Data were obtained from 158 CSF samples from 145 dogs with focal, noninfectious/noninflammatory neurologic disease. The effect of lesion location and the duration and severity of clinical signs were studied. One hundred and twenty-five samples were obtained from the cerebellomedullary cistern (CMC), and 33 were obtained from the lumbar cistern (LC). Intracranial and cervical disease affected the CSF from the CMC more often than did thoracolumbar disease. However, lumbar CSF was more frequently affected by disease anywhere along the neuraxis. For compressive spinal cord disease, the protein concentration at both cisterns was more often high in acute, clinically severe lesions.
Intracranial lesions consistently caused abnormalities in CSF from both the CMC (7 of 7; 100%) and LC (2 of 2;100%). Abnormalities were identified in 16 of 38 (42%) and 5 of 7 (71%) CMC and LC samples, respectively, in dogs with cervical disease. In dogs with thoracolumbar lesions, only 22 of 80 (27.5%) CMC samples were abnormal, compared with 21 of 24 (87.5%) LC samples. These findings suggest that CSF collected cranial to the lesion may be normal or only mildly altered by focal neurologic disease. Fluid obtained caudal to the lesion presumably is more substantially altered because of the predominant caudal flow of CSF. To maximize the yield of diagnostic information from CSF analysis, the fluid should preferably be obtained caudad to the disease site; however, because of problems associated with lumbar puncture, we suggest that CSF from the CMC also be obtained.